Syngene International Limited
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.
What Syngene files
- Investor Meet96
- Others83
- Important38
- Updates17
- Board Meeting13
- PPTs10
Syngene International Limited has scheduled a one-on-one virtual meeting with True Beacon PMS to discuss general business updates, with strict adherence to non-disclosure of any unpublished price sensitive information during the interaction.
Syngene International Limited has informed the Exchange about the Communication regarding remittance of final dividend for the FY 2025-26.
Syngene International granted 1,426,061 Performance Share Units (PSUs) to employees. This incentive plan allows conversion to shares at Rs. 10 per PSU after a 3-year vesting. It aligns employee interests with company growth but will lead to equity dilution.
Syngene International will participate in the Goldman Sachs Asia Leaders Conference 2026 in Hong Kong from August 31 to September 1. The company plans to hold in-person group and one-on-one meetings with analysts/institutional investors during this event.
Syngene International has acquired a minimum 7.93% stake in Ampin C&I Power Twelve Private Limited for ₹2.52 Cr. This investment is a key strategic move to secure renewable power supply, significantly reduce Syngene's energy costs, and lower its carbon footprint. The acquisition directly supports the company's decarbonization goals and commitment...